## Abstract ## Objectives We evaluated the efficacy and safety of long‐acting risperidone for 48‐week period in Korean patients. ## Methods This was a non‐randomized, open‐label, single‐centered, 48‐week study. Each of the participants visited the hospital every 2 weeks, and injections were give
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
✍ Scribed by Eva Lindström; Bo Eriksson; Anders Hellgren; Lars von Knorring; Göran Eberhard
- Book ID
- 116096382
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 687 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0149-2918
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot a
## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi